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Effects of Ocimum Basilicum on Functional 
Dyspepsia: a Double-Blind Placebo-
Controlled Study 
 
 
 
Abstract 
Background: Traditionally some people employ Ocimum 
basilicum (Shaspram) to relieve the symptoms of dyspepsia. 
We therefore studied the effects of oral extract of this medici-
nal plant on functional dyspepsia. 
 
Methods: In a double-blind placebo-controlled clinical trial, 
the effect of a four-week treatment of Shaspram was evaluated 
on functional dyspepsia. Two hundred cases from all patients 
referred for dyspepsia without having any obvious pathologic 
signs were randomly divided into case and control groups (100 
each). The hydroalcoholic extract of leaves of Shaspram was 
prepared and used. Patients were asked to have 30 drops of pre-
scribed medications (placebo or the extract, equal to 1.5 gram 
leaves powder) daily at 30 min before lunch and dinner for 
four-weeks. Severity was scored for each symptom on a num-
bered scale and the results compared with the results of placebo 
group or pretreatment period. 
 
Results: Patients in drug group responded to treatment better 
than patients in placebo group (P<0.001). Shaspram was more 
effective in female and young patients. Patients with functional 
dyspepsia that had dysmotility problems also responded to 
Shaspram better than others. 
 
Conclusion: Ocimum basilicum seems to relieve the symptoms 
of functional dyspepsia especially in female and young patients 
with dysmotility. 
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Introduction 
yspepsia refers to an intermittent or recurrent pain or 
discomfort centered in the upper abdomen.1 It is a 
common problem affecting up to one forth of adults in 
western countries.2 Most patients with dyspepsia do not show a 
structural or biochemical abnormality identified on routine diag-
nostic procedures to explain the problem.2 These patients are 
considered to have functional or non-ulcer dyspepsia (NUD).3 
The pathophysiological mechanisms of non-ulcer dyspepsia 
are poorly understood.4 It has been related to a variety of ab-
normalities including delayed gastric emptying of solid food,4 
failure of gastric fundus relaxation postprandially,5 visceral 
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hypersensitivity to mechanical distension,3,4 
and H pylori infection.2 Non-ulcer dyspepsia 
affects a heterogeneous group of patients.6 
Therefore, attempts have been made to cate-
gorize them based on symptom clusters.6 
Talley and his colleagues have divided NUD 
into three symptom subgroups.6 1) Ulcer-like 
dyspepsia in which pain is centered in the up-
per abdomen as the predominant symptom. 2) 
Dysmotility-like dyspepsia, in which unpleasant 
or troublesome non painful sensation is cen-
tered in the upper abdomen as the predominant 
symptom, and other symptoms including upper 
abdominal fullness, early satiety, bloating, or 
nausea. 3) Unclassified or nonspecific dyspep-
sia in which symptoms do not fulfill the criteria 
for ulcer-like or dysmotility-like dyspepsia. 
The categorization of dyspepsia was intro-
duced for the sake of better treatment. For 
example, patients with dysmotility-like symp-
toms should respond best to prokinetics, 
whereas patients with ulcer-like dyspepsia 
should respond best to antisecretory therapy.4,6 
Other groups of medications for NUD include 
antacids, cytoprotectors, H pylori eradicators, 
visceral hypersensitivity reducers, antispasmod-
ics, antidepressants, and antiemetics have 
been employed for treatment of NUD, how-
ever, none of them are satisfactory.6 
Ocimum basilicum (Shaspram4) is a me-
dicinal plant, which is used to reduce inflam-
mation and itching,7 cough and bronchitis, 
chills and common colds, nervous exhaustion, 
mental fatigue, melancholy or fear.7 It is also 
used to treat hyperlipidemia, and infections. It 
has been recommended to relieve symptoms 
of dyspepsia. In this study we have investi-
gated the effects of hydroalcoholic extract of 
Shaspram on functional dyspepsia. 
 
Patients and Methods 
 
A double-blind placebo controlled clinical trial 
was conducted to compare the effects of a 
four-week treatment of Shaspram with control 
group on functional dyspepsia. Participants 
were selected from those referring to the Edo-
scopy division in Haajar Hospital of Shahre-
kord University, Shahrekord, Iran, for dyspep-
sia. The patients had functional dyspepsia for 
at least three months. A total of 200 patients 
with functional dyspepsia, who were more than 
15 years old, and had non ulcer dyspepsia in 
endoscopic examinations, were invited to par-
ticipate in the trial. Patients were designated 
into drug and control groups. Patients with a 
history of previous peptic ulcer disease, having 
symptoms related to irritable bowel syndrome, 
biliary disease, pregnancy, daily intake of non-
steroidal anti-inflammatory drugs (NSAIDs), 
bismuth, and antibiotic, intake of H2-blockers or 
proton pump inhibitors were excluded. Patients 
with organic causes of gastroparesis (e.g. dia-
betes mellitus) and other serious diseases (in-
cluding drug dependencies, any bowel surgery 
or malignancy) and patients having mild dys-
pepsia were also excluded. 
 
Methods 
Proper information regarding the use of 
medications was provided to patients and 
informed consent was obtained before entry. 
Severity was scored for each symptom on a 
numbered scale (1 to 4 for each symptom) which 
is accepted as a tool for evaluating symptoms.8,9 
Patients were designated as mild (1-13), moder-
ate (14-26), severe (27-39), and very severe (39-
52), based on the total dyspepsia score (52).9 
Hydroalcoholic extract of Shaspram, ob-
tained from Gol-daru, Isfahan, Iran) was pre-
pared by percolation method by keeping 1.5 
kg of leaves powder in 2.2 liters of 80o ethyl 
alcohol for 48 hrs and then filtered.10 The re-
sultant extract was evaporated in 80°C, to 
have a solution with final volume of about 160 
ml. Then, 100 ml ethyl alcohol was added to 
this solution, to increase the solubility and final 
volume of the solution was reached to two lit-
ters by adding distilled water. The placebo was 
the base of the extract containing 5o ethyl alco-
hol solution. The resultant solution and the pla-
cebo were placed in similar and separate drop 
containers and coded 1 and 2 by a pharmacist. 
The gastroenterologist prescribed the drugs 
with codes of 1 or 2, without of being aware of 
the contents until the end of the study. Patients 
were asked to have 30 drops of prescribed 
medications (placebo or the extract, equal to 
1.5 g leaves powder) daily at 30 min before 
lunch and dinner. The patients were visited by 
the gastroenterologist every 8-10 days for four 
weeks to a checkup and get the assurance of 
taking their daily medications. After a four-week 
treatment period, the obtained results were 
compared with those of pretreated period and 
placebo treated group. 
 
Statistical analyses 
Symptoms obtained from patients were 
designated as mild (1-13), moderate (14-26), 
severe (27-39), and very severe (39-52), 
based on the total dyspepsia score of 52.9 Re-
sults of Shaspram treated and placebo groups 
before and after treatment are compared using 
c2 test. Student’s t-test was also used to com-
pare the severity of scores between the two 
groups and p<0.05 was considered as statisti-
cally different. 
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Results 
 
The mean±SD ages of drug and placebo 
treated groups were 42±11 and 39±10.6 yrs 
respectively. Sixty percent of patients of 
Shaspram treated group and 70% of placebo 
group were female. There were no statistical 
differences for age, or sex in two groups be-
fore treatment. The number of patients in rela-
tion to functional dyspepsia subtypes (Table 1), 
or severity of functional dyspepsia (Table 2), 
were statistically the same. 
Only five patients from placebo group and 
two patients from Shaspram treated group did 
not follow the four-week study procedures and 
dropped out. These patients were substituted 
with new participants. 
Patients in drug group responded to treat-
ment better than patients in placebo group 
(Table 2; p<0.001). Patients of drug treated 
group with dysmotility-like dyspepsia showed 
80.25% and patients with other subtypes of 
functional dyspepsia demonstrated 43.75% 
reductions in the severity score (p<0.05). 
 
Discussion 
 
The aim of this study was to assess the effect 
of Shaspram on functional dyspepsia. Patients 
in Shaspram treated group responded to 
treatment better than those of in placebo 
group. Since the pathophysiology of functional 
dyspepsia is imperfectly understood, it is diffi-
cult to evaluate the mechanisms involved in 
the effect of Shaspram on functional dyspep-
sia. Disturbed sensory function, disturbed mo-
tor function, duodenogastric reflux, increased 
gastric acid secretion, mucosal inflammation, 
H pylori infection, psychosocial factors and 
alterations of the central nervous system are 
factors which have been postulated to be in-
volved in the pathogenesis of functional dys-
pepsia.2,6 Therefore, more than one of these 
factors may interact with the effects of 
Shaspram on functional dyspepsia.7 
Patients with dysmotility problems (pure 
dysmotility-like, reflux-dysmotility, ulcer dys-
motility-like and ulcer-reflux dysmotility-like 
dyspepsia) benefited from Shaspram more 
than others. The relevance of gastrointestinal 
motor disturbances in functional dyspepsia 
has already been established.3 Eugenol, the 
major chemical content of Shaspram, has 
been shown to reduce gastrointestinal motil-
ity.7 However, other mechanisms might get 
involved in the effects of Shaspram on func-
tional dyspepsia. It is so because prokinetic 
drugs, which increase GI motility, have shown 
to be useful in functional dyspepsia.9 Eugenol 
has also demonstrated an anti-stress activity, 
a factor that may cause dyspepsia.11 In this 
regard, Shaspram was found to possess a sig-
nificant antiulcer activity against stress-induced 
ulceration in experimental animals,11 and this 
may strengthen this conclusion. 
Shaspram has been demonstrated to de-
crease acid and pepsin outputs.12 These ef-
fects enhance gastric mucosal strength and 
possibly reduce the  generation of peptic ulcer 
and thereby benefit patients with dyspepsia.6 
The extract of Shaspram has also yielded ap-
preciable quantities of linoleic acid,7 which has 
been shown to possess significant anti-
inflammatory activity.13 This effect was related 
to inhibition of arachidonate metabolism by 
linoleic acid.13 It has been suggested that li-
noleic acid of Shaspram blocks both cyclo-
oxygenase and lipo-oxigenase pathways of 
arachidonate metabolism which is responsible 
for the anti-inflammatory activity of this 
agent.13 Therefore, it seems that Shaspram 
might have multiple mechanisms responsible 
for the improvement of functional dyspepsia. 
 
Conclusion 
 
A mutual anti-inflammatory and antidyspepsia 
(or antiulcer) effect of Ocimum bacilicum is 
notable. Most anti-inflammatory drugs, such as 
non-steroidal anti-inflammatory drugs or glu-
cocorticosteroids, induce peptic ulcer or dys-
Table 1: Number of patients in relation to functional dyspepsia subtypes (FDS) at the beginning of the study in Shaspram 
treated and placebo groups 
Ulcer-like Dysmotility-like  Nonspecific 
Gender # Gender # Gender # FDS Age (yrs) 
Male  Female  Male  Female Male Female 
Total 
Treated 42±11 15 21 22 35 3 4 100 
Placebo 39±11 11 32 15 32 4 6 100 
 
Table 2: Number of patients before and after treatment 
based on the severity of functional dyspepsia 
group treatment MI # MO # S # VS # 
*before 0 52 43 5 Treated **after 79 5 13 3 
before 0 46 48 6 Placebo after 26 32 36 6 
Mild (MI; 1-13), Moderate (MO; 14-26), Severe (S; 27-
39), and very severe (VS; 39-52), based on the total 
dyspepsia score (52).9 
*p<0.05 between treated and placebo groups before 
treatment. 
**P<0.001 between treated and control groups follow-
ing treatment 
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pepsia. Therefore, patients with inflammatory 
disorders along with gastrointestinal disease 
may tolerate Ocimum bacilicum, a natural prod-
uct, better than non-steroidal anti-inflammatory 
or steroid drugs. 
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